Experienced in Alpha-1 Antitrypsin Deficiency (AATD)

Dr. Barry L. Schlansky

Hepatology
Kaiser Permanente
Interstate Medical Office Central
3600 N Interstate Avenue, 
Portland, OR 
Accepting New Patients
Experienced in Alpha-1 Antitrypsin Deficiency (AATD)
Kaiser Permanente
Interstate Medical Office Central
3600 N Interstate Avenue, 
Portland, OR 
OverviewInsuranceLocationsClinical Research

Overview

Barry Schlansky is a Hepatologist in Portland, Oregon. Dr. Schlansky is rated as an Experienced provider by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). His top areas of expertise are Hepatitis, Alcoholic Cirrhosis, Hepatitis C, Nonalcoholic Steatohepatitis (NASH), and Liver Transplant. Dr. Schlansky is currently accepting new patients.

His clinical research consists of co-authoring 19 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Specialties
Hepatology
Licenses
Internal Medicine in OR
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser
  • EPO
  • HMO
  • POS
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO

Locations

Interstate Medical Office Central
3600 N Interstate Avenue, Portland, OR 97227

Additional Areas of Focus

Dr. Schlansky has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3

19 Total Publications

African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis.
African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis.
Journal: Hepatology communications
Published: July 11, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schlansky's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      View All 19 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile